Hepatic iron influences responses to combination therapy with peginterferon alfa and ribavirin in chronic hepatitis C

Hepato-Gastroenterology

Volumn 55, Issue 85, 2008, Pages 1412-1415

  Lin, Tsung Jung ^a   Liao, Li Ying ^a   Lin, Chih ^a   Chang, Ting An ^a   Liu, Shu O ^a  

^a TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Chronic hepatitis C; Hepatic iron; Hepatitis C virus; Peginterferon; Ribavirin

Indexed keywords

ALPHA2A INTERFERON; ANTIVIRUS AGENT; FERRITIN; IRON; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A; RIBAVIRIN; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HEPATITIS C; HUMAN; MALE; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; IRON; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; TRANSFERRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 58149396735     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR: Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102:2108-2113.
2. Riggio O, Montagnese F, Fiore P, Folino S, Giambartolomei S, Gandin C, Merli M, Quinti I, Violante N, Caroli S, Senofonte O, Capocaccia L: Iron overload in patients with chronic viral hepatitis: how common is it? Am J Gastroenterol 1997; 92:1298-1301. (Pubitemid 27328587)
3. Piperno A, D'Alba R, Fargion S, Rof. L, Sampietro M, Parma S, Arosio V, Fare M, Fiorelli G: Liver iron concentration in chronic viral hepatitis: a study of 98 patients. Eur J Gastroenterol Hepatol 1995; 7:1203-1208. (Pubitemid 26030857)
4. Bacon BR, Britton RS: The pathology of hepatic iron overload: a free radical-mediated process? Hepatology 1990; 11:127-137. (Pubitemid 20075113)
5. Bonkovsky HL, Banner BF, Rothman AL: Iron and chronic viral hepatitis. Hepatology 1997; 25:759-768. (Pubitemid 27106467)
6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiftman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
7. Fried MW, Shiffman ML, Reddy KR, Smith C, Merinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
8. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill SM; PEGASYS International Study Group: Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
9. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS: Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994; 20:410-415. (Pubitemid 24082514)
10. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schiff ER, Bacon BR: Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995; 108:1104-1109.
11. Pianko S, McHutchison JG, Gordon SC, Heaton S, Goodman ZD, Patel K, Cortese CM, Brunt EM, Bacon BR, Blatt LM: Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. J Interferon Cytokine Res 2002; 22:483-489. (Pubitemid 34579551)
12. Distante S, Bjoro K, Helium KB, Myrvang B, Berg JP, Skaug K, Raknerud N, Bell H: Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002; 22:269-275. (Pubitemid 34846366)
13. Hofer H, Osterreicher C, Jessner W, Penz M, Steindl-Munda P, Wrba F, Ferenci P: Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 2004; 40:1018-1022. (Pubitemid 38670137)
14. Rulyak SJ, Eng SC, Patel K, McHutchison JG, Gordon SC, Kowdley KV: Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. Am J Gastroenterol 2005; 100:332-337. (Pubitemid 40314517)
15. Carlo C, Daniela P, Giancarlo C: Iron depletion and response to interferon in chronic hepatitis C. Hepatogastroenterology 2003; 50:1467-1471. (Pubitemid 37186511)
16. The French METAVIR Cooperative Study Group: Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20:15-20.
17. MacSween RNM, Burt AD, Portmann BC, Ishak KG, Scheuer PJ, Anthony PP: Pathology of the Liver. 4th Edition. Edinburgh, Churchill Livingstone, 2001; p. 260.
18. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y: Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73:673-679.
19. Hoffmann RM, Diepolder HM, Zachoval R, Zwiebel FM, Jung MC, Scholz S, Nitschko H, Riethmuller G, Pape GR: Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 1995; 21:632-638.
20. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV: Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118:346-355. (Pubitemid 30067508)
21. Marinho RT, Pinto R, Santos ML, Lobos IV, Moura MC: Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C. J Viral Hepat 2004; 11:206-216. (Pubitemid 38658445)
22. Ishii K, Sumino Y, Shionhara M, Higami K, Matsumaru K, Fujita Y, Sasao K, Wakui N, Shinohara M, Nagai H, Watanabe M, Miki K: Early immune-mediated response to ribavirin combined with IFN in patients with chronic hepatitis C. Hepatol Res 2006; 34:15-22. (Pubitemid 43091871)
23. Lohr HF, Schmitz D, Arenz M, Weyer S, Gerken G, Meyer zum Buschenfelde KH: The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. J Hepatol 1999; 31:407-415. (Pubitemid 29408721)
24. Walker EM Jr, Walker SM: Effects of iron overload on the immune system. Ann Clin Lab Sec 2000 Oct; 30:354-365.
25. Kakizaki S, Takagi H, Horiguchi N, Toyoda M, Takayama H, Nagamine T, Mori M, Kato N: Iron enhances hepatitis C virus replication in cultured human hepatocytes. Liver 2000; 20:125-128. (Pubitemid 30219138)
26. Theurl I, Zoller H, Obrist P, Datz C, Bachmann F, Elliott RM, Weiss G: Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3. J Infect Dis 2004; 190:819-825. (Pubitemid 39050013)
27. Serejo F, Emerit I, Filipe PM, Fernandes AC, Costa MA, Freitas JP, de Moura MC: Oxidative stress in chronic hepatitis C: the effect of interferon therapy and correlation with pathological features. Can J Gastroenterol 2003; 17:644-650. (Pubitemid 37536844)
28. Morisco F, Verde V, Fogliano V, Ritieni A, Marmo R, De Luise G, Tuccillo C, Caporaso N: Oxidative status in chronic hepatitis C: the influence of antiviral therapy and prognostic value of serum hydroperoxide assay. Free Radic Res 2004; 38:573-580. (Pubitemid 38701754)
29. Baynes RD: Assessment of iron status. Clin Biochem 1996; 29:209-215.
30. Yu ML, Dai CY, Lin ZY, Lee LP, Hou HL, Hsieh MY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL: A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006; 26:73-81.
31. Lin TJ, Lin CL, Wang CS, Liu SO, Liao LY: Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan. World J Gastroenterol 2005; 11:3905-3908.